CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner.

ABSTRACT: Combining immunotherapy with targeted therapy has increasingly become an appealing therapeutic paradigm for cancer treatment due to its great potential for generating durable and synergistic antitumor response. In this study, however, we unexpectedly found that two types of CpG-based tumor peptide vaccine treatments consistently negated the antitumor activity of a selective BRAF inhibitor in tumors with BRAF mutation rather than showing a synergistic antitumor effect. Our further studies demonstrated that CpG alone was sufficient to dampen BRAF inhibitor-induced antitumor responses, suggesting that the impaired antitumor activity of the BRAF inhibitor observed in mice receiving CpG-based peptide vaccine is mainly dependent upon the use of CpG. Mechanistically, CpG increased the number of c

SUBMITTER: Huang L 

PROVIDER: S-EPMC5509483 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature